Trans-acitretin is metabolized to etretinate. Significance for oral retinoid therapy;TRANS-ACITRETIN WIRD IN ETRETINAT RUCKMETABOLISIERT. BEDEUTUNG FUR DIE ORALE RETINOIDTHERAPIE

Hautarzt

Volumn 47, Issue 3, 1996, Pages 173-177

  Almond Roesler, Brigitte ^a,b   Orfanos, Constantin E ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

13 cis acitretin; ethanol; etretinate; re esterification; trans acitretin

Indexed keywords

ALCOHOL; ETRETIN; ETRETINATE; KETOCONAZOLE; PHENOBARBITAL; RETINOID; RIFAMPICIN;

CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FETUS MALFORMATION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PSORIASIS; REVIEW;

ACITRETIN; ADMINISTRATION, ORAL; ANIMALS; BIOTRANSFORMATION; DRUG MONITORING; ESTERIFICATION; ETRETINATE; FEMALE; HALF-LIFE; HUMANS; KERATOLYTIC AGENTS; PREGNANCY; PSORIASIS; TREATMENT OUTCOME;

EID: 0029887752     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050398     Document Type: Review

References (29)

1. Bauer R, Orfanos CE (1981) Trimethyl-methoxyphenylretinoid acid (Ro 10-1670) inhibits mitogen-induced DNA-synthesis in peripheral blood lymphocytes in vitro. Br J Dermatol 105: 19-24
2. Berbis P, Bun H, Al Mallah NR, Durand A, Rognin C (1988) Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. Dermatologica 177: 244-246
3. Bolt HM, Kappas H, Remmer H (1973) Studies on the metabolism of ethynylestradiol in vitro and in vivo: the significance of 2-hydroxylation and the formation of polar products. Xenobiotica 3: 773-785
4. Brindley CJ (1989) Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). Dermatologica 178: 79-87
5. Chou RC, Wyss R, Huselton CA, Wiegand U-W (1991) A newly discovered xenobiotic metabolic pathway: ethyl ester formation. Life Sci 49: pl169-pl172
6. Chou RC, Wyss R, Huselton CA, Wiegand U-W (1992) A potentially new metabolic pathway: ethyl esterification of acitretin. Xenobiotica 22: 993-1002
7. Cotler S, Chang D, Henderson L, Garland W, Town C (1992) The metabolism of acitretin and isoacitretin in the in situ isolated perfused rat liver. Xenobiotica 22: 1229-1237
8. Geiger J-M, Brindley CJ (1988) Cis-trans-interconversion of acitretin in man. Skin Pharmacol 1: 230-236
9. Geiger J-M, Baudin M, Saurat J-H (1994) Teratogenic risk with etretinate and acitretin treatment. Dermatology 189: 109-116
10. Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, Wokalek H, Hoting E (1988) Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 19: 458-469
11. Gollnick H, Rinck G, Bitterling T, Orfanos CE (1990) Pharmakokinetik von Etretinat, Acitretin und 13-cis-Acitretin: neue Ergebnisse und Nutzen der Blutspiegel-onentierten klinischen Anwendung. Z Hautkr 65: 40-50
12. Jensen BK, Milazzo JJ, Lin A (1987) Dose proportionality of acitretin at oral doses ranging from 25 to 100 mg in the absence of food. Abstract PP-666, Pharmac Res 4: 95
13. Jensen BK, Chaws CL, Huselton CA, Mico BA (1992) Clinical evidence that acitretin is esterified to etretinate when administered with ethanol. FASEB 6: 3669
14. Lambert WE, Meyer E, De Leenheer AP, De Bersaques J, Kint AH (1992) Pharmacokinetics and drug interactions of etretinate and acitretin. J Am Acad Dermatol 27: 19-22
15. Larsen FG, Jakobsen P, Larsen CG, Norgaard A, Kragballe K, Nielsen-Kudsk F (1987) Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacol Toxicol 61: 85-88
16. Larsen FG, Jakobsen P, Larsen CG, Kragballe K, Nielsen-Kudsk F (1988) Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis. Pharmacol Toxicol 62: 159-165
17. Larsen FG, Jakobsen P, Eriksen H, Grønhoøj J, Kragballe K, Nielsen-Kudsk F (1991) The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. J Clin Pharmacol 31: 477-483
18. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F (1993) Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 100: 623-627
19. Laugier JP, De Sousa G, Bun H, Geiger J-M, Surber C, Rahmani R (1994) Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatology 188: 122-125
20. McNamara PJ, Jewell RC, Jensen BK, Brindley CJ (1988) Food increases the bioavailability of acitretin. J Clin Pharmacol 28: 1051-1055
21. Meyer E, De Bersaques J, Lambert WE, De Leenheer AP, Kint AH (1993) Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. Acta Derm Venerol (Stockh) 73: 113-115
22. Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34: 459-503
23. Paravicini U, Camenzind M, Gower M, Geiger J-M (1985) Multiple dose pharmacokinetics of Ro 10-1670, the main metabolite of etretinate (Tigason): In: Saurat JH (ed) Retinoids: New trends in research and therapy, Karger, Basel, pp 289-292
24. Pilkington T, Brogden RN (1992) Acitretin. A review of its pharmacology and therapeutic use. Drugs 43: 597-627
25. Rinck G, Gollnick H, Orfanos CE (1989) Duration of contraception after etretinate. Lancet II:845-846
26. Stuck AE, Brindley CJ, Busslinger A, Frey FJ (1989) Pharmacokinetics of acitretin and its 13-cis-metabolite in patients on haemodialysis. Br J Clin Pharm 27: 301-304
27. Tsambaos D, Orfanos CE (1981) Chemotherapy of psoriasis and other skin disorders with oral retinoids. Pharmac Ther 14: 355-374
28. Watkins PB (1990) Role of cytochromes in drug metabolism and hepatotoxicity. Seminars In Liver Disease 10: 235-250
29. Wiegand U-W, Jensen BK (1991) Pharmacokmetics of acitretin in humans. In: Saurat JH (ed) Retinoids: 10 Years on. Basel. Karger, pp 102-203